Berg, Stacey L <br/><br/>
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2005 
 - 3376-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2005.03.426  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Arabinonucleosides--administration & dosage<br/>Child<br/>Child, Preschool<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Infant<br/>Infusions, Intravenous<br/>Leukemia, T-Cell--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Neoplasm Staging<br/>Recurrence<br/>Risk Assessment<br/>Survival Rate<br/>Treatment Outcome